Biotech firm Windtree Therapeutics announced plans to purchase up to $700 million worth of BNB, following the digital asset's recent all-time high price of $808. The company trades on Nasdaq under the ticker WINT and aims to strengthen its balance sheet with BNB acquisitions. Initially, Windtree had planned to buy $200 million worth of BNB but has since raised that figure by securing $520 million to support its purchases. The funding will come from a $500 million equity line of credit and a $20 million stock-purchase arrangement with Build and Build Corp. Windtree will collaborate with crypto exchange Kraken for asset custody. CEO Jed Latkin emphasized the importance of obtaining additional funding for this strategy, which reflects a growing trend among publicly traded companies to build crypto treasuries. Alongside Windtree, other firms such as Nano Labs have also announced substantial investments in BNB, highlighting the increasing acceptance of cryptocurrencies in corporate treasury strategies.

Source 🔗